Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.39 |
| ▸ | CDK1 | P06493 | 1/20 | 0.39 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.39 |
| ▸ | GSK3A | P49840 | 1/20 | 0.39 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.39 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.39 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.39 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.38 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 5/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.37 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.36 |
| ▸ | FYN | P06241 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4470177 | 0.80 | TDP1 (0.41) | KDM4EALDH1A1LMNATDP1CCNB2 | |
| SCHEMBL23557730 | 0.78 | SLC22A12 (0.39) | KDM4EALDH1A1LMNATDP1CCNB2 | |
| SCHEMBL4488950 | 0.76 | KDM4E (0.40) | KDM4EALDH1A1LMNATDP1CCNB2 | |
| SCHEMBL4367442 | 0.72 | TDO2 (0.44) | CCNB2CDK1CCNB1GSK3AGSK3B | |
| SCHEMBL23557732 | 0.71 | FYN (0.38) | KDM4EALDH1A1LMNATDP1CCNB2 | |
| SCHEMBL28296292 | 0.71 | LRRK2 (0.40) | KDM4EALDH1A1TDP1LRRK2CYP11B2 | |
| SCHEMBL18123835 | 0.70 | SQOR (0.38) | KDM4EALDH1A1CYP11B2MAPKAPK2 | |
| SCHEMBL4378433 | 0.69 | MEN1 (0.48) | KDM4EEGLN2CYP11B2CYP19A1MMP3 | |
| SCHEMBL21928359 | 0.69 | EGLN2 (0.43) | KDM4EALDH1A1CCNB2CDK1CCNB1 | |
| SCHEMBL1840144 | 0.69 | MAP4K4 (0.43) | CCNB2CDK1CCNB1GSK3AGSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7572808-B2 | Triazolopyridine cannabinoid receptor 1 antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-08-11 | — | — | US | disclosed |
| US-7572808-B2 | Triazolopyridine cannabinoid receptor 1 antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-08-11 | — | — | US | disclosed |
| EP-1891068-A1 | TRIAZOLOPYRIDINE DERIVATIVES AS CANNABINOID RECEPTOR 1 ANTAGONISTS | Bristol-Myers Squibb Company (US) | 2008-02-27 | — | — | EP | disclosed |
| US-20070004772-A1 | Triazolopyridine cannabinoid receptor 1 antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2007-01-04 | — | — | US | disclosed |
| US-20070004772-A1 | Triazolopyridine cannabinoid receptor 1 antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2007-01-04 | — | — | US | disclosed |
| WO-2006138695-A1 | TRIAZOLOPYRIDINE DERIVATIVES AS CANNABINOID RECEPTOR 1 ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004772-A1 | Triazolopyridine cannabinoid receptor 1 antagonists | CNR1, CNR2, TRPV1 | KDM4E 3120/4885ALDH1A1 1668/4885LMNA 4035/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.